BIO Europe
即将召开的会议
Flexible solutions for biotech companies at every value inflection point
Expertise for Every Modality in Early Development
Certara offers new, emerging and VC-backed biotech companies a modern and data driven approach to drug development. Starting with the end in mind, Certara’s cross functional experts will support your team to further your scientific insights, optimize resources, and de-risk your therapy development journey.
Expertise for every modality:
- Small molecules, Biologics (monoclonal antibodies, ADCs)
- Complex biologics (Bispecific Abs, siRNA, oligonucleotides)
- Cell and Gene Therapies, Vaccines, Drug-device combos and Devices
Certara Strategy Early Development Solutions
从候选药物筛选到 I 期临床试验的每个阶段，均提供专家支持
从候选药物筛选到成功开展I期临床试验，成功应对这一过程中的挑战需要丰富的药物开发经验和专业知识。药物开发因其成本高、耗时长和高淘汰率而面临独特的挑战。确保您的候选药物在早期开发中采用最佳方法至关重要。在早期阶段取得成功为获得资金支持和建立合作关系铺平了道路，为您在后续阶段取得持续成功打下了基础。
Strategic Partnerships for Early Development Success
Are you spending too much time managing multiple consultants/vendors, telling them what to do, and hoping your timelines don’t slip? Certara offers a strategic partnership that streamlines your early development work, allowing you to focus on what matters most.
Certara’s solutions:
- A full team of cross-functional virtual drug developers
- Relationships with individual experts who become an integrated part of your team
- Strategic recommendations from a collaborative partner invested in your success
Certara played a key role in Biohaven’s approval of Nurtec, contributing to the company’s acquisition by Pfizer for almost $12B. Check out a video testimonial here.
Our comprehensive services have recently helped clients:
- Achieve an accelerate approval in pediatric oncology
- Avoid the costly expense of entering Phase 1 with a starting dose that was too low
- Reach significant milestones in development and regulatory approval
Additional Resources
